Transplantation proceedings最新文献

{"title":"Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients","authors":"Aina Quilis ,&nbsp;Eva Gavela ,&nbsp;Julia Kánter ,&nbsp;Cristina Castro-Alonso ,&nbsp;Emma Calatayud ,&nbsp;Elena Vivó ,&nbsp;Manuel Parra ,&nbsp;Paula Gandia ,&nbsp;Asunción Sancho","doi":"10.1016/j.transproceed.2024.12.009","DOIUrl":"10.1016/j.transproceed.2024.12.009","url":null,"abstract":"<div><h3>Background</h3><div>The potential anti-proteinuric effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) is of special interest in kidney transplantation. Its benefits have been demonstrated in diabetic kidney transplant recipients (KTRs). We analyzed the efficacy and safety of SGLT2i in non-diabetic KTRs collecting clinical and analytical data at baseline and 6 months after the introduction of the drug.</div></div><div><h3>Methods</h3><div>We performed a unicenter observational study including all non-diabetic KTRs who were prescribed SGLT2i as antiproteinuric therapy. We analyzed clinical and analytical data at baseline and after 6 months of starting SGLT2i.</div></div><div><h3>Results</h3><div>We included 22 patients (68.2% men), median age 58 years, with a median post-transplant period of 67 months. Hypertension was present in 95% of the patients, 90% had dyslipidemia, and 68.2% were receiving treatment with renin-angiotensin-aldosterone system blockade agents plus antialdosterone drugs. The most used SGLT2i was dapagliflozin (91%). The median baseline creatinine was 2.1 (1.48 to 2.85) mg/dL, estimated glomerular filtrate rate (eGFR) 31 (23.7 to 45,2) mL/min, and urinary protein/creatinine ratio 1.68 (0.58 to 2.9) g/g. After 6 months of follow-up, we found a significant reduction in proteinuria (1.68 to 1.06 g/g, <em>P</em> = .025), as well as a reduction in uric acid and high-density lipoprotein (HDL). There was a mild significant reduction in eGFR (31 to 28.5 mL/min, <em>P</em> = .001), which was greater in patients with recurrence of the underlying disease or chronic rejection. The drug was discontinued in two patients (9.1%): one due to a urinary tract infection (UTI) and another one due to hemodialysis initiation. There were no cardiovascular events or death.</div></div><div><h3>Conclusions</h3><div>The use of SGLT2i in our cohort was effective to reduce proteinuria in non-diabetic KTRs after 6 months of treatment with an acceptable safety profile.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 24-26"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for Moderate-risk Delisting in Highly Sensitized Patients","authors":"Carolina Castro Hernández ,&nbsp;Daniel de la Sierra ,&nbsp;Mónica Renuncio-García ,&nbsp;Dzmitry Mikhalkovich ,&nbsp;Nerea Mota-Pérez ,&nbsp;Alejandra Comins-Boo ,&nbsp;Juan Irure-Ventura ,&nbsp;María Valentín-Muñoz ,&nbsp;Juan Carlos Ruiz-San Millán ,&nbsp;Marcos López-Hoyos ,&nbsp;David San Segundo","doi":"10.1016/j.transproceed.2024.12.008","DOIUrl":"10.1016/j.transproceed.2024.12.008","url":null,"abstract":"<div><h3>Background/Aim</h3><div>Despite the donor-exchange program implementation for highly sensitized (HS) patients, no improvement in waiting list in those HS patients with 100% calculated panel reactive of antibodies (cPRA) is observed. Recently, it has been published the treatment with imlifidase in desensitization algorithm. However, there are low-risk strategies to reduce cPRA. A cPRA of &lt;99.95% increase donor offer chances, so delisting (DL) strategies should be addressed in cPRA reduction. We propose an integral approach for DL from low to intermediate risk to assess the 100% HS patients on waiting list.</div></div><div><h3>Methods</h3><div>The common DL criteria for previously forbidden alleles were that they should neither have been present in previous transplants nor possess complement fixation ability. Low-risk phase of DL is based on historical mean fluorescence intensity (MFI) of &lt;5000 in the last 2 years. The next phase risk is based on single-antigen test in 1/10 diluted serum with MFI value of &lt;3000; without eplet mismatch (low-intermediate risk specificity), or with eplet mismatch from previous transplants (intermediate risk). The molecular mismatch may be assessed with the mismatch calculator tool from registry website (<span><span>https://www.epregistry.com.br/</span><svg><path></path></svg></span>).</div></div><div><h3>Conclusions</h3><div>Low-risk DL approaches are now widely used to reduce cPRA in HS patients; however, sometimes it is not enough to get transplanted and new tools are needed. Despite new treatments with imlifidase, some cases had anti-human leukocyte antigen rebound levels with a higher risk of rejection. Here, we propose a scaled DL approach would be a better therapeutic approach for HS patients whenever possible.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 13-15"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title page - THE 8th CONGRESS of the SPANISH TRANSPLANTATION SOCIETY (SET 2024)Bilbao, Spain","authors":"","doi":"10.1016/S0041-1345(25)00014-4","DOIUrl":"10.1016/S0041-1345(25)00014-4","url":null,"abstract":"","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Page 1"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preservation of Liver Graft Using the Hypothermic Oxygenated Perfusion (HOPE) System: A single-center experience","authors":"Beatriz Villota Tamayo ,&nbsp;Arkaitz Perfecto Valero ,&nbsp;Patricia Ruiz Ordorica ,&nbsp;Alberto Ventoso Castiñeira ,&nbsp;Gerardo Moro Portela ,&nbsp;Jaime Encinas Gutiérrez ,&nbsp;Ibone Palomares Etxeberria ,&nbsp;Mikel Prieto Calvo ,&nbsp;Sara Mambrilla Herrero ,&nbsp;Teresa Pascual Vicente ,&nbsp;Eunate Muga Ibarreche ,&nbsp;María Senosiain Labiano ,&nbsp;Mikel Gastaca Mateo","doi":"10.1016/j.transproceed.2024.12.006","DOIUrl":"10.1016/j.transproceed.2024.12.006","url":null,"abstract":"<div><h3>Introduction</h3><div>The hypothermic oxygenated perfusion (HOPE) system has been developed to improve the quality of previously considered suboptimal liver grafts, reduce complications, and increase the number of available donors. The aim of this study is to evaluate the results since its implementation in the liver transplant (LT) program at our center.</div></div><div><h3>Materials and Methods</h3><div>We conducted a retrospective descriptive analysis of all LTs with HOPE from August 2022 to November 2023 with a minimum follow-up of 3 months. The indication criteria included: donor &gt;75 years, macrovesicular steatosis (&gt;30%) confirmed by biopsy, donor &gt;70 years with additional risk factors (macroscopic steatosis or grossly suboptimal liver), anticipated cold ischemia time &gt;6 hours, and donation after circulatory death with suboptimal graft or laboratory results.</div></div><div><h3>Results</h3><div>Of the 96 LTs performed during this period, HOPE was used in 12 cases (12.5%). Two patients (16.7%) experienced postreperfusion syndrome, and one (8.3%) early allograft dysfunction was noted. Four patients (33.3%) had major surgical complications (Clavien-Dindo ≥ III). The median peak of ALT during the first 48 hours was 438.5 U/L (range 128-2475). There were two biliary complications (16.7%), one venous complication (8.3%), and two arterial complications (16.7%). With a median follow-up of 7.8 months, both patient survival and graft survival were 100%.</div></div><div><h3>Conclusion</h3><div>In our experience, the use of HOPE seems to reduce ischemic damage and shows good short- and medium-term results.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 55-58"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Transplantation for Polycystic Disease: Experience and Results of a Single-Center Series","authors":"Teresa Pascual Vicente ,&nbsp;Arkaitz Perfecto Valero ,&nbsp;Beatriz Villota Tamayo ,&nbsp;Patricia Ruiz Ordorica ,&nbsp;Gerardo Moro Portela ,&nbsp;Alberto Ventoso Castiñeira ,&nbsp;Jaime Encinas Gutierrez ,&nbsp;Ibone Palomares Etxeberria ,&nbsp;Mikel Prieto Calvo ,&nbsp;Sara Mambrilla Herrero ,&nbsp;Patricia Salvador Bengoechea ,&nbsp;Javier Bustamante Schneider ,&nbsp;Mikel Gastaca Mateo","doi":"10.1016/j.transproceed.2024.12.011","DOIUrl":"10.1016/j.transproceed.2024.12.011","url":null,"abstract":"<div><div>Polycystic liver disease (PLD) is a hereditary condition, and its symptoms are due to the growth of cysts. Liver transplantation (LT) is the only curative treatment. A retrospective single-center analysis was conducted on the 10 LTs performed for PLD between 2004 and 2023. Eighty percent of the patients were women, and 70% had polycystic hepatorenal involvement. Forty percent required a kidney transplant prior to LT, and in 30%, simultaneous hepatorenal transplantation was performed due to end-stage chronic kidney failure. In 70% of cases, hepatectomy was performed with vena cava preservation (the piggy-back technique). The median operative time was 235 minutes (range 190–398), and the mean weight of the explanted liver was 5050g (range 1840–9450). Two patients had major complications classified as ≥IIIa on the Clavien-Dindo scale: a hemorrhage from the phrenic artery and a hepatic artery anastomotic stenosis, both resolved through interventional radiology. The rate of surgical reoperation and postoperative mortality was zero. The median stay in the Intensive Care Unit was 4 days (range 3–7), and the median hospital stay was 17 days (range 10–25). No patient required re-transplantation. After a median follow-up of 43.5 months (range 8–284), both patient and graft survival were 100%. Overall, and based on our experience, LT provides excellent outcomes and it is the treatment of choice for PLD in patients with end-stage liver failure or clinically limiting symptoms.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 48-51"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracorporeal Photopheresis, a Therapeutic Alternative for T cell-mediated Rejection in Renal Transplantation","authors":"Mercedes de Lara Gil ,&nbsp;Mercedes Gil Muñoz ,&nbsp;Elena de Lara Gil ,&nbsp;Miguel Blanquer ,&nbsp;Santiago Llorente Viñas ,&nbsp;Francisco Morales Caravaca ,&nbsp;Isabel Saura Luján ,&nbsp;Juan Bautista Cabezuelo Romero","doi":"10.1016/j.transproceed.2024.11.028","DOIUrl":"10.1016/j.transproceed.2024.11.028","url":null,"abstract":"<div><div>T-cell mediated rejection (TCMR) in renal transplantation, although reduced by better immunosuppressants, still impacts graft survival. TCMR responds to methylprednisolone (MPL) in 60% to 70% of cases, with polyclonal anti-T-lymphocyte antibodies (ATGs) used for severe or corticoresistant cases. When ATG is contraindicated, extracorporeal photopheresis (ECP) may be an alternative. ECP involves treating immune cells with 8-methoxypsoralen and ultraviolet-A radiation before reinjection, with effect in various T-cell-mediated and autoimmune diseases.</div><div>This study included two renal transplant recipients with severe TCMR. Patient 1’s creatinine levels were 1.4 mg/dL baseline, 2.2 mg/dL at TCMR diagnosis, and 1.9 mg/dL at ECP initiation. Patient 2’s levels were 1 mg/dL baseline, 1.8 mg/dL at diagnosis, and 1.42 mg/dL at ECP initiation. The THERAKOS CELLEX system was used for patient 1, and the OPTIA system was used for patient 2, both with methoxsalen. ECP is highlighted as a viable option for TCMR in renal transplantation when conventional treatments are unsuitable.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 16-18"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Approach to Vascular Thymic Tissue Transplantation in Humans: A Case Report","authors":"Luis F. Tintinago-Londoño ,&nbsp;Francisco J. Jaramillo-Echeverry ,&nbsp;Tania M. Guzmán ,&nbsp;Juan C. Bravo-Ocaña ,&nbsp;Nhora M. Silva-Pérez ,&nbsp;José Abella-Calle","doi":"10.1016/j.transproceed.2024.11.036","DOIUrl":"10.1016/j.transproceed.2024.11.036","url":null,"abstract":"<div><h3>Background</h3><div>Vascular thymus transplantation has been explored in animal models but remains untested in humans. Current approaches to congenital athymia involve avascular transplantation of allogeneic thymic tissue, which may delay immune recovery. Building on animal studies, we propose revascularization of thymic tissue in a human model. This case report details about the revascularization of neonatal thymic tissue in an elderly woman with terminal cancer, evaluating revascularization efficacy, rejection risks, and procedural safety over a 3-week period.</div></div><div><h3>Case report</h3><div>A thymic tissue graft obtained from a neonate during corrective heart surgery was implanted into the left radial forearm of an 85-year-old woman. The graft was evaluated for 3 weeks, with one thymic vein anastomosed to the cephalic vein and one thymic artery to the radial artery. No immunosuppression or HLA matching was employed. Weekly Doppler ultrasound and postexplantation histopathology monitored blood flow and graft status. Hematologic, biochemical, radiological evaluations, and daily clinical follow-up were conducted.</div></div><div><h3>Conclusion</h3><div>This preliminary research demonstrates the feasibility of revascularizing a neonatal thymus in an adult using microsurgical techniques.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 138-142"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Predictive of Success in Uncontrolled Donation After Circulatory Death in the Community of Madrid: An Analysis of Data From the Regional Registry of Donation and Transplantation (CORE Registry)","authors":"Ana María Pérez-Alonso ,&nbsp;Cristina Horrillo-García ,&nbsp;Alonso Mateos-Rodríguez ,&nbsp;Ana María Cintora-Sanz ,&nbsp;César Cardenete-Reyes ,&nbsp;Alicia Gutierrez-Misis","doi":"10.1016/j.transproceed.2024.11.023","DOIUrl":"10.1016/j.transproceed.2024.11.023","url":null,"abstract":"<div><div>Unfortunately, organ donation remains a challenge today. In Spain, uncontrolled Donation after Circulatory Death was introduced in cardiorespiratory arrests witnessed by out-of-hospital emergency services (OHES) to increase the number of donors. However, the selection of donor patients remains a challenge today.</div></div><div><h3>Aim</h3><div>to identify the variables that influence the number of organs for donation obtained from patients attended OHES. To use these variables to create a predictive model of transplant success.</div></div><div><h3>Method</h3><div>A retrospective, descriptive, analytical, cross-sectional study based on data from the Regional Registry of Donation and Transplantation (CORE registry) of the Community of Madrid from 2007 to 2017. Descriptive bivariate analysis was performed relating the organ donor (yes/no) variable with each of the study variables. Logistic regression models were performed with the variables and showed statistical significance using as principal variable the organ donor (yes/no) variable.</div></div><div><h3>Results</h3><div>A total of 550 patients were included. Mean age was 46.2 years (SD: 8.7), 86.4% (<em>n</em> = 473) male. Bivariate analysis found a relationship between the variable organ donor (yes/no) and age, weight, and body mass index (BMI) with <em>P</em> &lt; .05. The predictive model showed the highest number of donors in the 45 to 55 years age group and BMI 25 to 30. Those aged over 60 with a BMI of 30 and above had a probability of organ donation of 40% or less.</div></div><div><h3>Conclusions</h3><div>In uncontrolled Donation after Coronary Death involving OHES there is a relationship between organ donation and age and BMI. Patients aged 45 to 55 with a BMI of 25 to 30 more frequently donate organs.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 2","pages":"Pages 159-167"},"PeriodicalIF":0.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Lung Transplant Recipients: A Single Center Report","authors":"Claire E. Fishman ,&nbsp;Ciara Walshe ,&nbsp;Tamara Claridge ,&nbsp;Stephanie Witek ,&nbsp;Krishna Pandya ,&nbsp;Jason D. Christie ,&nbsp;Joshua M. Diamond ,&nbsp;Michaela R. Anderson","doi":"10.1016/j.transproceed.2024.11.016","DOIUrl":"10.1016/j.transproceed.2024.11.016","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetes and obesity increase risk of death after lung transplantation. Optimal treatment of diabetes and obesity may improve post-transplant outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are FDA-approved to treat diabetes and obesity and demonstrate improvement in renal and cardiovascular outcomes in the general population. However, side effects may limit tolerability in lung transplant recipients. We hypothesized that GLP-1RA would be stopped due to side effects in a higher proportion of lung transplant recipients compared to the general population but result in weight loss for those who were able to tolerate them.</div></div><div><h3>Methods</h3><div>We performed a single-center case series of lung transplant recipients initiated on a GLP-1RA post-transplant between April 1, 2005 and December 31, 2023. We assessed side effects and complications during GLP-1RA use. Weight was assessed at time of GLP-1RA initiation and 3-, 6-, and 12-months postinitiation.</div></div><div><h3>Results</h3><div>Fifty-nine lung transplant recipients initiated a GLP-1RA during the study period with a median (IQR) total time of use of 590 (280-891) days. Thirty-seven percent (22/59) stopped the medication due to side effects, with nausea and vomiting being most common. The median (IQR) percent change in weight at 12-months post-GLP-1RA initiation was -2.5% (-8.7% to 1.5%).</div></div><div><h3>Discussion</h3><div>We report the largest study evaluating GLP-1RA use in lung transplant recipients. Discontinuation rates are higher and weight loss is lower than in the general population. However, most lung transplant recipients tolerated long-term use of GLP-1RA. Further work is required to identify which recipients are most likely to benefit and how to optimize tolerability.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 2","pages":"Pages 342-347"},"PeriodicalIF":0.8,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paired Exchange Living Donor Liver Transplantation: A Single Center Experience From Turkiye","authors":"Ayhan Dinckan ,&nbsp;Eryigit Eren ,&nbsp;Fatih Ensaroglu ,&nbsp;Taylan Sahin ,&nbsp;Hakan Parlak ,&nbsp;Ali Kocyigit ,&nbsp;Utku Alkara ,&nbsp;Murat Akyildiz ,&nbsp;Mehmet Tokac","doi":"10.1016/j.transproceed.2024.11.002","DOIUrl":"10.1016/j.transproceed.2024.11.002","url":null,"abstract":"<div><h3>Background</h3><div>In countries with low rates of deceased donor solid organ transplantations, live-donor liver transplantation is the preferred definitive treatment for children and adults with end-stage liver disease. However, it is known that a remarkable number of potential living liver donors are rejected due to ABO incompatibility, suboptimal liver mass, or anatomical features. Paired exchange liver transplantation (PELT) practice emerged to overcome these obstacles. Herein, we present the results of our single-center experience with PELT and compare them with previously reported data.</div></div><div><h3>Methods</h3><div>Patients who underwent PELT between January 2015 and December 2022 constituted the target population. The collected recipient data included demographic parameters, the model for end-stage liver disease score, graft-recipient weight ratio, indication for LT and paired exchange, body-mass index, duration of hospital stay, duration of intensive care unit stay, postoperative complications and inpatient mortality. Donor data, including demographic characteristics, body mass index, type of liver graft (right lobe or left lateral segment), graft weight (g), type of portal vein anatomy (Type 1, 2, or 3), type of biliary anatomy (Type 1, 2, 3a, 3b), duration of hospital stay, complications and mortality were retrieved.</div></div><div><h3>Results</h3><div>Among 18 recipients, 14 (78%) were male, and 4 (22%) were female. The mean recipient age was 50.7 [2-66], while the mean donor age was 29.3 [18-40]. The mean follow-up period was 31.9 [12-71] months. The 1-year patient and graft survivals were calculated as 83.3% and 88.9%.</div></div><div><h3>Conclusion</h3><div>The PELT can be utterly feasible at transplant centers with remarkable LDLT experience.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 2","pages":"Pages 272-276"},"PeriodicalIF":0.8,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}